REHOVOT, Israel, March 1,
2023 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN)
(TASE: EVGN), a leading computational biology company focused
on revolutionizing product discovery and development in multiple
life-science based industries, today announced that it will attend
and meeting with investors at the 35th Annual ROTH Conference being
held in Dana Point, California on
March 13-14, 2023.
The conference will feature one-on-one and small group meetings,
industry panels, presentations and fireside chats. The Roth
conference typically draws thousands of attendees, including
institutional investors, analysts, family offices and high
net-worth investors.
Evogene's Executive VP, Business Development, Eyal Ronen, will be in attendance at the
conference on Monday, March 13 and
will be participating in one-on-one meetings with analysts and
investors.
Investors that wish to meet with Mr. Ronen are welcome to
coordinate the meeting via their Roth representatives.
Alternatively, they may contact Evogene's investor relations team
which can coordinate meetings either face-to-face at the conference
or alternatively via an online virtual meeting in the weeks
following.
About Evogene Ltd.:
Evogene (Nasdaq: EVGN) (TASE: EVGN) is a computational biology
company aiming to revolutionize the development of life-science
based products by utilizing cutting edge technologies to increase
the probability of success while reducing development time and
cost. Evogene established three unique tech-engines -
MicroBoost AI, ChemPass
AI and GeneRator AI – leveraging Big Data
and Artificial Intelligence and incorporating deep
multidisciplinary understanding in life sciences. Each
tech-engine is focused on the discovery and development of
products based on one of the following core components: microbes
(MicroBoost AI), small molecules (ChemPass AI), and
genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through
subsidiaries and strategic partnerships. Evogene's subsidiaries
currently utilize the tech-engines to develop human
microbiome-based therapeutics by Biomica, ag-biologicals by
Lavie Bio, ag-chemicals by AgPlenus,
medical cannabis products by Canonic and castor varieties, for the
biofuel and other industries, by Casterra.
Investor Relations Contact
Kenny Green
E: kenny.green@evogene.com
T: +1 212 378 8040
Logo - https://mma.prnewswire.com/media/1947468/Evogene.jpg
View original
content:https://www.prnewswire.com/news-releases/evogene-to-attend-the-annual-roth-investor-conference-in-california-on-march-13-2023-301759417.html
SOURCE Evogene